Medicines regulation, pricing and reimbursement in Brazil
Brazil is an upper-middle-income country with a high human development index (HDI) of 0.765 (2019). The Unique Health System (SUS) is a universal, decentralised system, free at point-of-care, although 27% of Brazilians have voluntary supplementary health insurance. Medicines are provided free-of-ch...
Main Authors: | Adriana M. IVAMA-BRUMMELL, Daniella PINGRET-KIPMAN, Priscila G. LOULY, Rosiene R. ANDRADE |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde
2022-03-01
|
Series: | Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde |
Online Access: | https://rbfhss.org.br/sbrafh/article/view/769 |
Similar Items
-
Pharmaceutical Pricing and Reimbursement Policies: lessons learnt and perspectives for Brazil
by: Adriana M. IVAMA-BRUMMELL, et al.
Published: (2022-12-01) -
Pharmaceutical regulation, pricing, coverage and policy reform in the United States of America
by: Mariana P. SOCAL, et al.
Published: (2022-09-01) -
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
by: Agnes Vitry
Published: (2015-12-01) -
Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries
by: Juan Carlos Rejon-Parrilla, et al.
Published: (2023-11-01) -
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context
by: Adriana M. Ivama-Brummell, et al.
Published: (2023-06-01)